Neuronetics and Greenbrook TMS Finalize Merger Agreement
Neuronetics, Inc. (NASDAQ: STIM) and Greenbrook TMS Inc. have officially announced the completion of their merger. This strategic move involves Neuronetics acquiring all outstanding common shares of Greenbrook. The transaction marks a significant advancement in the provision of mental health treatments, particularly in the realm of therapy options.
A Transformative Step in Mental Health Innovation
The merger is set to transform the landscape of mental health therapy in the United States. Keith Sullivan, the President and CEO of Neuronetics, expressed excitement about this integration, stating that it positions the Combined Company to significantly improve patient access to essential mental health treatments. With a robust network and innovative technology combined under one roof, Neuronetics aims to enhance its value proposition to shareholders while fostering a mission dedicated to better mental health care.
Strengthening Access to Advanced Therapies
Through the arrangement, Greenbrook's shares will no longer be available for trading on the OTCQB Market. Neuronetics intends to streamline operations by terminating Greenbrook's public reporting obligations, focusing instead on delivering superior mental health services through its extensive treatment network. This is anticipated to lead to greater efficiency and effectiveness in addressing the needs of those experiencing mental health challenges.
Advancing Neuroscience Treatment Solutions
Neuronetics is already a recognized leader in neuroscience, particularly noted for their NeuroStar Advanced Therapy for Mental Health. This innovative, non-invasive treatment has been shown to deliver impressive results, especially for patients suffering from conditions like major depressive disorder. Following the merger, the organizations can better synergize their offerings to enhance treatment protocols.
Vision for Future Growth and Integration
Both Neuronetics and Greenbrook are committed to maintaining operational excellence during this transition period. According to Sullivan, the integration teams have initiated significant plans to merge the best practices of both organizations. The goal is to not only drive profitable growth but also ensure positive cash flow.
Commitment to Patient Care
Bill Leonard, the CEO of Greenbrook, also shared insights about the merger's potential. He highlighted how combining resources will allow the companies to provide innovative solutions to patients suffering from depression. The alignment of values and commitment to the mental health sector positions Neuronetics and Greenbrook to build a robust future together.
Key Information for Shareholders
Former shareholders of Greenbrook are advised to submit their letters of transmittal to Computershare Investor Services Inc. to receive their entitled share considerations resulting from the merger. Those holding shares through brokers or dealers should ensure they follow the necessary steps outlined by their intermediaries.
Contacting Computershare
For any questions or further assistance, former shareholders can reach out to Computershare via telephone or email. This is particularly important in light of potential delivery delays due to external factors affecting postal services.
About Neuronetics
Neuronetics, Inc. is at the forefront of redefining mental health treatment. With a focus on integrating advanced technological solutions like the NeuroStar system and offering comprehensive treatment options, Neuronetics aims to improve patient outcomes. This commitment includes ensuring that its innovative therapies are accessible to a wider audience, especially those who have struggled with conventional treatment approaches.
Frequently Asked Questions
What is the significance of the merger between Neuronetics and Greenbrook?
The merger enhances the delivery of mental health treatments by combining Neuronetics' innovative technologies with Greenbrook's established treatment network.
How does this transaction impact Greenbrook shareholders?
Greenbrook shareholders will need to submit letters of transmittal to Computershare in order to receive their corresponding shares in the merged company.
What treatments are offered by the Combined Company?
The Combined Company focuses on advanced mental health therapies, including NeuroStar TMS and Spravato for patients dealing with depression.
What is NeuroStar Advanced Therapy?
This is a non-invasive treatment designed for mental health conditions, providing significant improvement for patients when traditional treatments have failed.
How does Neuronetics plan to maintain operational excellence?
Neuronetics has set an immediate focus on integrating the two companies effectively while implementing strategic initiatives aimed at achieving profitable growth.
